RAPID AND ACCURATE DETERMINATION OF THE ANTIBIOTIC RESISTANCE (AMR) PROFILES OF PATHOGENIC BACTERIA IS A NATIONAL PRIORITY OWING TO ITS IMPORTANCE TO SUSTAINABLE AGRICULTURE AND PUBLIC HEALTH. THE CENTERS FOR DISEASE CONTROL ESTIMATES THAT ANTIBIOTIC-RESISTANT BACTERIA CAUSE TWO MILLION ILLNESSES AND 23,000 DEATHS ANNUALLY IN THE US. THE RISE IN AMR WOULD COST THE WORLD UP TO 100 TRILLION USD BY 2050. NEARLY 80% OF ANTIBIOTICS SOLD IN THE US ARE USED IN LIVESTOCK TO PREVENT INFECTION, PROMOTE GROWTH, AND IMPROVE YIELD. THE ANTIBIOTICS GIVEN TO LIVESTOCK CAN TRANSFER TO HUMANS BY MEAT PRODUCTS, AND TO SOIL AND WATER SYSTEMS BY LIVESTOCK EXCRETIONS. TO REDUCE THE EXCESSIVE USE OF ANTIBIOTICS, MAINTAIN THE SUSTAINABILITY OF AGRICULTURE, AND PROTECT HUMAN HEALTH, THE PROJECT AIMS TO DEVELOP A POINT-OF-CARE BIOSENSOR TECHNOLOGY THAT CAN RAPIDLY PROFILE DRUG SUSCEPTIBILITY. CURRENTLY, DUE TO THE SLOW TURNOVER OF CONVENTIONAL AMR DETECTION ASSAYS, PHYSICIANS OFTEN PRESCRIBE BROAD-SPECTRUM ANTIBIOTICS IN CASE OF INFECTIONS. AS A RESULT, 1/3 TO 1/2 OF USED ANTIBIOTICS ARE UNNECESSARY. SUCH A PRACTICE IS ACCELERATING THE SPREAD OF AMR. BASED ON THE RECENT ADVANCES IN MICROFLUIDICS AND NANOPHOTONICS, THE PROPOSED ON-CHIP GENOTYPIC BIOSENSOR CAN CHARACTERIZE AMR GENES WITHIN TWO HOURS. THE MEASURED THE AMR PROFILE WILL ENABLE MORE PRECISE AND EFFECTIVE USES OF ANTIBIOTICS. IF SUCCESSFUL, THE PROPOSED BIOSENSOR TECHNOLOGY WILL BE CAPABLE OF PERFORMING ON DEMAND ANALYSIS IN VETERINARY DIAGNOSTIC LABS, EMERGENCY MEDICAL SERVICES, AND DEVELOPING COUNTRIES.